Oncology · Neuroendocrine TumoursTrial Updateclinicalmid-term

Phase 2 Study of AUR103 Calcium in Advanced Neuroendocrine Tumours Initiated

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/17/2026, 12:30:44 PM

Assessment confidence: 63% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the Phase 2 study for AUR103 Calcium is significant as it could establish a new treatment option in the oncology space for neuroendocrine tumors. Success in this trial may strengthen AUR103 Pharma's market position and attract further investment and partnerships. Regulatory context from FDA (FDA AP — LEUCOVORIN CALCIUM (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (8 high-relevance).

Strategic Assessment

Success in this trial may enhance the company's portfolio in oncology and attract interest from investors and partners. The strongest clinical anchor is A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer (ClinicalTrials.gov), sponsor/company relevance (astrazeneca); patient population match (advanced). In Oncology · Neuroendocrine Tumours, 8 regulatory and 5 competitive items passed relevance filtering for AUR103 Pharma.

Competitive Pressure

The most relevant competitive pressure comes from Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) (Merck) — sponsor/company relevance (merck); patient population match (advanced). Secondary pressure from Phase III Trial Evaluates Cemiplimab with Surgery for Advanced Skin Cancer.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — LEUCOVORIN CALCIUM (SUPPL) (FDA). Moderate corpus alignment. The outcomes of this trial will be critical for future regulatory submissions and could influence labeling and approval processes for AUR103 Calcium.

Key Risks

Elevated medium regulatory exposure for AUR103 Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, AUR103 Calcium could capture market share in a niche area of oncology, potentially leading to increased revenue and competitive positioning against other therapies for neuroendocrine tumors.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC).
Upside for AUR103 Pharma may improve if A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Upside for AUR103 Pharma may improve if A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (ClinicalTrials.gov) delivers favorable follow-through.
Success in this trial may enhance the company's portfolio in oncology and attract interest from investors and partners.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for efficacy and safety outcomes, as well as any announcements regarding patient enrollment and interim analyses.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — ATORVASTATIN CALCIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — CALCIUM ACETATE (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — CALCIUM GLUCONATE (ORIG)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA AP — LEUCOVORIN CALCIUM (SUPPL)
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca); Patient population match (advanced)
FDA document
View source
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca); Patient population match (advanced)
FDA document
View source
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.govmedium relevance
Patient population match (advanced)
FDA document
View source
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
ClinicalTrials.govmedium relevance
Patient population match (advanced)
FDA document
View source

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (Merck); Patient population match (advanced)
FDA document
View source
Phase III Trial Evaluates Cemiplimab with Surgery for Advanced Skin Cancer
Humanexa Signalshigh relevance
Entity match (oncology); Patient population match (advanced)
CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial
Humanexa Signalshigh relevance
Entity match (oncology); Patient population match (advanced)
Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated
Humanexa Signalshigh relevance
Entity match (oncology)
Phase III Trial of SYHA1813 Shows Promise for High-Grade Meningiomas
Humanexa Signalshigh relevance
Entity match (oncology)

Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Entity match (oncology)
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AUR103 Pharma
Oncology

Commercial impact

medium

If successful, AUR103 Calcium could capture market share in a niche area of oncology, potentially leading to increased revenue and competitive positioning against other therapies for neuroendocrine tumors.

Regulatory impact

medium

The outcomes of this trial will be critical for future regulatory submissions and could influence labeling and approval processes for AUR103 Calcium.

What to watch

Monitor trial results for efficacy and safety outcomes, as well as any announcements regarding patient enrollment and interim analyses.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.